Privileged scaffolds for library design and drug discovery - Test2 - elhamkhani - TriplyDB

Privileged scaffolds for library design and drug discovery

Privileged scaffolds for library design and drug discovery

http://www.wikidata.org/entity/Q24604575

about

The azaindole framework in the design of kinase inhibitors Rapid preparation of triazolyl substituted NH-heterocyclic kinase inhibitors via one-pot Sonogashira coupling-TMS-deprotection-CuAAC sequence Unique motifs and hydrophobic interactions shape the binding of modified DNA ligands to protein targets Rhodanine hydrolysis leads to potent thioenolate mediated metallo-β-lactamase inhibition The Molecule Cloud - compact visualization of large collections of molecules Integration of Microfractionation, qNMR and zebrafish screening for the in vivo bioassay-guided isolation and quantitative bioactivity analysis of natural products The open access malaria box: a drug discovery catalyst for neglected diseases Large-scale chemical similarity networks for target profiling of compounds identified in cell-based chemical screens Privileged Structures Revisited.Highly stereoselective synthesis of natural-product-like hybrids by an organocatalytic/multicomponent reaction sequence.Pharmacologic profiling of phosphoinositide 3-kinase inhibitors as mitigators of ionizing radiation-induced cell death Exploration of Scaffolds from Natural Products with Antiplasmodial Activities, Currently Registered Antimalarial Drugs and Public Malarial Screen Data.The Rhodadyns, a New Class of Small Molecule Inhibitors of Dynamin GTPase Activity.Metal-free C-H alkylation of heteroarenes with alkyltrifluoroborates: a general protocol for 1°, 2° and 3° alkylation.Privileged diazepine compounds and their emergence as bromodomain inhibitors.Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis Novel pyrrolopyrimidine-based α-helix mimetics: cell-permeable inhibitors of protein−protein interactions Structure-based repurposing of FDA-approved drugs as TNF-α inhibitors.2,3-Substituted quinoxalin-6-amine analogs as antiproliferatives: a structure-activity relationship study Anti-Mycobacterial Evaluation of 7-Chloro-4-Aminoquinolines and Hologram Quantitative Structure-Activity Relationship (HQSAR) Modeling of Amino-Imino Tautomers.Solid-phase synthesis and chemical space analysis of a 190-membered alkaloid/terpenoid-like library Bis-aryloxadiazoles as effective activators of the aryl hydrocarbon receptor.Synthesis of novel molecular probes inspired by harringtonolide.Screening and hit evaluation of a chemical library against blood-stage Plasmodium falciparum.Recent trends and observations in the design of high-quality screening collections.A cycloisomerization/Friedel-Crafts alkylation strategy for the synthesis of pyrano[3,4-b]indoles Direct, catalytic, and regioselective synthesis of 2-alkyl-, aryl-, and alkenyl-substituted N-heterocycles from N-oxides.Shape-based virtual screening with volumetric aligned molecular shapes Application of a sequential multicomponent assembly process/huisgen cycloaddition strategy to the preparation of libraries of 1,2,3-triazole-fused 1,4-benzodiazepines.Evolution of a strategy for preparing bioactive small molecules by sequential multicomponent assembly processes, cyclizations, and diversification APPLICATIONS OF MULTICOMPONENT ASSEMBLY PROCESSES TO THE FACILE SYNTHESES OF DIVERSELY FUNCTIONALIZED NITROGEN HETEROCYCLES.Iminosugars as therapeutic agents: recent advances and promising trends.Solid-phase synthesis of tetrasubstituted pyrrolo[2,3-d]pyrimidines.Multicomponent, Mannich-type assembly process for generating novel, biologically-active 2-arylpiperidines and derivatives.Strategies of multi-objective optimization in drug discovery and development.The concept of privileged structures in rational drug design: focus on acridine and quinoline scaffolds in neurodegenerative and protozoan diseases.Expedient synthesis of norbenzomorphan library via multicomponent assembly process coupled with ring-closing reactions BET bromodomain inhibitors: a patent review.Expanding the scope of PNA-encoded synthesis (PES): Mtt-protected PNA fully orthogonal to fmoc chemistry and a broad array of robust diversity-generating reactions.Discovery of structurally-diverse inhibitor scaffolds by high-throughput screening of a fragment library with dimethylarginine dimethylaminohydrolase.

P2860

Q27013668-5422A89B-B8F4-4C3D-9287-857999659016 Q27668090-E404BCE0-B7D6-4ED6-B0D4-37B97FA8B602 Q27675037-69F122BA-DF8B-4990-B869-19BED0339FB6 Q27696197-DF9222D6-6BD7-4C25-BC6E-192B2B02CAFC Q27768978-A2CA7B36-4C15-452C-8ACB-F9D15DE6B3DE Q28488352-C17F3A54-4BEF-42D3-BA0F-3631E86B040D Q28533977-A13A5807-A368-413B-A0DE-2EFE1C6C72F7 Q28545239-13E60A40-ACB4-45C6-BFE7-6D4DD904A1D5 Q30101030-B66016AB-FC83-4B98-A0E7-F659CB5E0EEF Q30316563-21857125-3252-4939-8FFF-15E9081DB400 Q30409339-4B893060-7845-42FC-963E-42DDAE3EA522 Q31037903-257E11E7-2EE2-4DB2-9E72-FF2DEBB6D46E Q33630482-96139E42-4CD0-4033-9F47-00D88DC2C297 Q33640571-DA036132-3FDD-4116-9861-10B762D23CC8 Q33671341-1A04468B-2746-4BEF-AEAB-D5548277A047 Q33745283-12C0F531-DF0B-47AF-8392-D06B661F6F16 Q33775959-FF4C5762-3FE6-4AFA-8927-4F793E067125 Q33834499-D90F45B6-5673-4FDB-B433-D24833537875 Q33837666-BDBEAA79-7D6B-4B2F-918C-2A4FCB18B945 Q33851536-D131A71A-1643-48FF-8B51-22A806D3299C Q33857987-1C54014D-D9F9-4E49-B2B6-0DB2009FD4E1 Q33861999-D15C79F3-3718-4F8D-A5CF-34E7A034A586 Q33887944-B02400FB-98AD-416B-A718-C6F93283DA0D Q33891625-AD5FC131-E5AC-4866-BA2E-852FF8593082 Q33893113-DA943250-5DAF-414D-92C2-09E7E982D794 Q33955677-5DBFEF7E-9AE1-4748-9ABE-FA1BB5E965C8 Q34053482-6FB5D6D7-BEF2-4A9E-BF57-A0C5A3E79E7A Q34076210-4568F27C-6395-49CC-956A-27F164E2D588 Q34138274-0E72B29B-3ED1-490B-AE1F-E8608924DB34 Q34207033-3AB42B85-EC7D-481C-A694-A71FCD0584BB Q34208947-1B185A3D-B895-4CB4-BD8D-91D0E8B1D818 Q34212463-05B1FAC5-D7D6-45FD-A33A-64C6DA0D0E85 Q34242633-4750A4C2-24C4-42D5-9730-E49714C0C5AC Q34245574-2FFFB8FA-1C2F-45B1-A98E-89FA235BB8EA Q34286000-BEBCD051-48CE-45DA-B425-4F32CF22B911 Q34286572-A463165D-EAC5-4112-8F9A-B0021C34E195 Q34362791-18A4057E-A6F5-456A-8C2E-5B5FEC7CDE7F Q34386777-B3B0434C-AE4A-4776-B0E3-C550A7BEF534 Q34390347-938D9846-336C-4F29-AC0C-688FB8BC48B6 Q34393366-8A0CD321-7674-4191-AECC-B92214728CC6

P2860

Privileged scaffolds for library design and drug discovery

http://www.wikidata.org/entity/Q24604575

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Privileged scaffolds for library design and drug discovery

@ast

Privileged scaffolds for library design and drug discovery

@en

Privileged scaffolds for library design and drug discovery

@nl

type

label

Privileged scaffolds for library design and drug discovery

@ast

Privileged scaffolds for library design and drug discovery

@en

Privileged scaffolds for library design and drug discovery

@nl

prefLabel

Privileged scaffolds for library design and drug discovery

@ast

Privileged scaffolds for library design and drug discovery

@en

Privileged scaffolds for library design and drug discovery

@nl

P1433

Q24604575-9DF5FA46-E826-475F-8D1C-11E92B3BCB01

P1476

Q24604575-C23AE914-927A-406D-88F8-820BEB46C892

P2093

Q24604575-936E09B0-8565-4778-9769-E20D3BD8E6C8

Q24604575-B59A0EEB-B843-4141-AD4F-D0FFBA8C5CB3

Q24604575-E00F058B-3CAC-499D-9193-DBF6244BED90

P2860

Q24604575-0148A4C0-E3DF-4D47-9BC8-BBE096C7106C

Q24604575-06F598CF-DF90-48D2-93F1-39F0F2614E95

Q24604575-0951071C-2D61-4FA2-8A5D-74600F6A9A20

Q24604575-103E94B6-50F4-4A0C-9B5E-7E177506CE17

Q24604575-1419C2AA-4542-4F43-9737-6FB8EE796373

Q24604575-19E13443-5A28-4743-9EB9-99F8CCE49CAF

Q24604575-267F2A1E-C71C-4FC5-AFE2-F687DF0E368D

Q24604575-338F6A86-CEF8-4AA7-B891-82FCEEEE0553

Q24604575-35FCB41C-7F4B-49EB-AB74-11B4348C26C3

Q24604575-3F16965B-48EA-4FE8-A550-D1585C3DCCC2

P304

Q24604575-3B70DEA9-48BA-4442-A071-2A72789DDB3D

P31

Q24604575-282D4898-B8C6-484D-B93B-6DEC47BB9D1C

P3181

Q24604575-F5944B3F-0E6D-4C59-B234-C83D8C148E0B

P356

Q24604575-E7477A5F-9CF5-48BE-BB07-EE3017D9149A

P407

Q24604575-8FD356B8-EDCD-45B5-90C6-9F2090336C62

P433

Q24604575-5A8C7B3E-CE97-4677-87C8-4F31642FE241

P478

Q24604575-A3496A0B-6E04-4B76-B74F-08A2B7F6E97D

P577

Q24604575-B4764D94-86CB-4FBC-BE00-454C2E6A4C56

P5875

Q24604575-9D76F709-47FE-4679-AF76-333DA4F4D778

P698

Q24604575-73D1D560-7B28-414F-B343-23E44C4B9A12

P921

Q24604575-C6EDED0A-D064-4226-986F-F1BB81D98952

P932

Q24604575-E1A564C6-2D8A-4193-97BC-64159F7CA9BB

P3181

P356

J.CBPA.2010.02.018

P1433

Current Opinion in Chemical Biology

P1476

Privileged scaffolds for library design and drug discovery

@en

P2093

Brent R Stockwell

http://www.w3.org/2001/XMLSchema#string

Matthew E Welsch

http://www.w3.org/2001/XMLSchema#string

Scott A Snyder

http://www.w3.org/2001/XMLSchema#string

P2860

Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors

Target-oriented and diversity-oriented organic synthesis in drug discovery

A planning strategy for diversity-oriented synthesis

The evolving role of natural products in drug discovery

Towards the optimal screening collection: a synthesis strategy

Drugs for bad bugs: confronting the challenges of antibacterial discovery

Discovery of estrogen sulfotransferase inhibitors from a purine library screen.

Combinatorial synthesis of 3-(amidoalkyl) and 3-(aminoalkyl)-2-arylindole derivatives: discovery of potent ligands for a variety of G-protein coupled receptors.

Libraries from natural product-like scaffolds.

Privileged molecules for protein binding identified from NMR-based screening.

P304

347-61

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4829993

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/J.CBPA.2010.02.018

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2010-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

42370281

http://www.w3.org/2001/XMLSchema#string

P698

20303320

http://www.w3.org/2001/XMLSchema#string

P921

P932

2908274

http://www.w3.org/2001/XMLSchema#string